EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failure

Melendhran Pillay iD, Manish C Choudhary, Rinki Deo, Serhiy Naumenko, Trevor J Tamura, Behzad Etemad, Gregory Edelstein, Aabida Khan, Kerusha Govender, Subitha Govender, Philip Tzou, Mary Mick und 19 weitere

PLOS Pathogens · 2026

DOI: 10.1371/journal.ppat.1014118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Melendhran Pillay und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, Durban, South Africa. Hauptthemen laut MEDLINE: HIV-1, Drug Resistance, Viral, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV-1 drug resistance remains a major challenge to treatment and control efforts, particularly in sub-Saharan Africa (sSA). However, standard resistance genotyping does not adequately capture linked drug resistance mutations within the viral quasispecies that may influence virologic failure (VF). We used a next-generation sequencing primer ID (NGS-Primer ID) assay to characterize linked HIV-1 drug resistance mutations in plasma from participants in the Resistance Testing to Improve Management of Virologic Failure (REVAMP) study who had detectable viremia on first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) and were maintained on NNRTI-based regimens. For each participant, we calculated a weighted genotypic susceptibility score (wGSS) based on the GSS of each reported pattern and its sequence-supported frequency within the sample. Plasma specimens from 108 participants were sequenced. Sanger sequencing showed a median GSS of 1.0 (IQR, 1.0-2.0), whereas NGS-Primer ID identified a median of 10 distinct resistance patterns per participant (IQR, 5–17), with 67% (IQR, 8–92) of reported DRM-pattern frequency within participants corresponding to linked dual-class mutations. A broad spectrum of drug-susceptible and resistant- DRM patterns were observed, with the median difference between the highest and lowest pattern-specific GSS being 2.0 (2.0-2.75). Within each participant, a median of 10% of reported patterns showed less resistance, while 19% showed more resistance compared to that predicted by Sanger sequencing. Individuals with persistent VF had significantly lower wGSS at study entry than those who later achieved virologic re-suppression (median, 1.3 vs 2.1; p < 0.001). NGS-Primer ID revealed substantial intra-host diversity in linked HIV-1 drug resistance patterns that was not captured by conventional Sanger sequencing. Incorporating linked resistance patterns into susceptibility assessment may improve prediction of subsequent virologic failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Drug Resistance, ViralHIV InfectionsAnti-HIV AgentsHumansFemaleMutationMaleHigh-Throughput Nucleotide SequencingGenotypeTreatment FailureGenetic VariationAdult

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Virology, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
  • School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, South Africa.
  • Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Department of Biostatistics, Harvard Chan School of Public Health, Boston, Massachusetts, United States of America.
  • Newborn Screening Ontario, Ottawa, Ontario, Canada.
  • Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, California, United States of America.

ORCID-Profile: Melendhran Pillay, Jonathan Z Li

Förderung

  • NIAID NIH HHS
  • NIH

Zitieren

APA

Pillay, M., Choudhary, M. C., Deo, R., Naumenko, S., Tamura, T. J., Etemad, B., Edelstein, G., Khan, A., Govender, K., Govender, S., Tzou, P., Mick, M., Herbert, Z. T., Muyindike, W., Moosa, M. S., Brijkumar, J., Sunpath, H., McCluskey, S., Chimukangara, B., …, & Li, J. Z. (2026). Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failure. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014118

Vancouver

Pillay M, Choudhary MC, Deo R, Naumenko S, Tamura TJ, Etemad B, et al. Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failure. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014118

BibTeX
@article{Pillay2026,
  author = {Pillay, Melendhran and Choudhary, Manish C and Deo, Rinki and Naumenko, Serhiy and Tamura, Trevor J and Etemad, Behzad and Edelstein, Gregory and Khan, Aabida and Govender, Kerusha and Govender, Subitha and Tzou, Philip and Mick, Mary and Herbert, Zachary T and Muyindike, Winnie and Moosa, Mahomed-Yunus Suleman and Brijkumar, Jay and Sunpath, Henry and McCluskey, Suzanne and Chimukangara, Benjamin and Manyana, Sontaga C and Gounder, Lilishia and Parboosing, Raveen and Francois, Kerri-Lee and Shafer, Robert and Ho Sui, Shannan and Pillay, Selvan and Marconi, Vincent and Siedner, Mark J and Moodley, Pravi and Msomi, Nokukhanya and Li, Jonathan Z},
  title = {Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failure},
  journal = {PLOS Pathogens},
  year = {2026},
  doi = {10.1371/journal.ppat.1014118}
}
Kostenlos starten →